Cannabinoid of the Month: Cannabigerol (CBG) | AusCannaReviews
Big Announcement!!
After two weeks of relentless dedication, I'm ecstatic to unveil: Buds & Bowls!
This electrifying event isn't just about entertainment—it's a revolutionary platform for education and advocacy for the medicinal cannabis community. Picture this: live music, captivating talks, and, drumroll please... a fierce lawn bowls tournament! If you find yourself in Brisbane on Saturday, April 20, 2024, mark your calendars and come join me at The Boo!
Don't miss out on a day packed with laughter, camaraderie, and unforgettable memories. Let's make it a day to remember together!
Tickets and more information: Buds & Bowls
Use AusReviews5 for $5 off your ticket!!
This month we’re taking a deeper look at Cannabigerol (CBG), a non-psychoactive cannabinoid found in cannabis plants.
CBG is a precursor to other cannabinoids, including THC and CBD and is often referred to as the mother of all cannabinoids. It is present in cannabis plants in relatively low concentrations compared to THC and CBD, making it a minor cannabinoid. However, its role as a precursor makes it an essential component in the biosynthesis of various cannabinoids, highlighting its importance in the plant's chemical profile.
While often overshadowed by its more popular counterparts like THC and CBD, CBG has garnered significant attention in recent years due to its potential therapeutic properties and versatile applications. Research into the therapeutic effects of CBG is still in its infancy, but preliminary studies suggest that it may have a range of potential health benefits. These include anti-inflammatory, neuroprotective, antibacterial, and mood-enhancing properties.
In 2022, the Australian Bureau of Statistics reported that just under 3.7 million people, constituting approximately 14.5% of the population in Australia, were living with arthritis. Arthritis encompasses a spectrum of inflammatory conditions affecting the joints, leading to symptoms such as pain, stiffness, and decreased mobility. A study published in January of 2023 in the International Journal of Molecular Sciences investigated the anti-inflammatory effects of CBG in Rheumatoid Arthritis (RA). The study found that CBG had robust anti-inflammatory effects on cytokine production, cell viability and antibody production. Therefore, CBG might be suited as an adjunct therapy for RA to reduce cytokine and autoantibody production.
A study published in Antioxidants an international, peer-reviewed, open-access journal, in January of 2020 investigated the role of CBD and CBG in regulating hypothalamic neuromodulators. The hypothalamus, a crucial brain region, is pivotal in regulating various physiological functions, including appetite, sleep, stress response, and hormone secretion. The endocannabinoid system, consisting of cannabinoid receptors and endocannabinoids, has been implicated in modulating hypothalamic function. The findings revealed that both CBD and CBG exert modulatory effects on hypothalamic neuromodulators. Specifically, CBG demonstrated modulatory actions on hypothalamic signalling pathways, suggesting its potential role in regulating neuroendocrine function and homeostasis.
In February 2023 a study was published in Biomedicines that examined the antibacterial effect of CBG. The study highlighted CBG's potential as a versatile antibacterial and anti-biofilm agent against Streptococcus mutans infections. Its capacity to address bacterial growth, membrane stability, biofilm formation, and quorum sensing mechanisms underscores its promise as a therapeutic approach for addressing dental caries and other bacterial infections. However, further investigation into CBG's mechanisms of action and effectiveness in clinical applications is still necessary to fully capitalize on its therapeutic benefits.
A case report published in Research in Veterinary Science in July of 2023 investigated whether combining cannabis and melatonin treatment with a rehabilitation program could improve symptoms in a dog with compulsive disorder. The dog was given a cannabis oil containing THC, CBD, and CBG, along with melatonin. This treatment regimen was also complemented by a customized behavioural program spanning five months. Observational findings showed obsessive behaviours, including tail chasing and pacing, were significantly reduced, and episodes of self-directed aggression diminished. Moreover, the dog displayed increased engagement in interactive play and improved overall quality of life.
If you’re looking for medicinal cultivars on the Australian market that are high in CBG**…
PUREKANN’s TLm Dry Flower (Cheese 101) (Total CBG 2.8%)
AURA Therapeutics’s Purple Raine (Total CBG 2.6%)
Chemovar’s Daily Grape (Total CBG <2%)
Cannatrek’s T23 Brooklyn (Total CBG 1.74%)
Bob’s Bob 24 (Total CBG 1.31%)
Kind Medical’s Taurus (Total CBG 1.04%)
Kind Medical’s Thea (Total CBG 0.964%)
Pouch’s Pouch Red (Total CBG 0.90%)
Cannatrek’s Jasper (Total CBG 0.897%)
Kind Medical’s Azure (Total CBG 0.66%)
**This data was provided by Catalyst by honahlee. The honahlee team requires all product suppliers to verify their cannabinoid percentages beyond the suppliers’ brochure or health professional marketing claims via a Certificate of Analysis (COA) with measured cannabinoid value for the products to be searchable.
This substack aims to provide anecdotal information from my personal experiences in hopes it will lead to meaningful conversations between my readers and their healthcare professionals about medicinal cannabis.
I have no formal training in medicine or science. This article does not constitute medical advice.